Moleculin Biotech (MBRX) Price & Analysis

Compare

1,632 Followers

MBRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.25 - $3.65

Previous CloseN/A

Volume63.82K

Average Volume (3M)2.74M

Market Cap

$16.52M

Enterprise Value-$2.45M

Total Cash (Recent Filing)$7.56M

Total Debt (Recent Filing)$292.00K

Price to Earnings (P/E)―

Beta1.80

Next Earnings

Nov 17, 2025

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding30,286,167

10 Day Avg. Volume1,216,615

30 Day Avg. Volume2,739,561

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.15

Enterprise Value/Revenue-19.44

Enterprise Value/Gross Profit87.48

Enterprise Value/Ebitda0.09

Forecast

1Y Price Target

$7.00

Price Target Upside1047.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAnnamycin achieved a 50% complete remission rate in a similar Phase 2 trial, suggesting potential effectiveness in the current study.

Preclinical DataPromising preclinical data support the potential of annamycin as a therapeutic agent for the treatment of liver cancers.

Regulatory ProgressPositive FDA feedback brings annamycin one step closer to clinical evaluation in pediatric cancer patients.

Bears Say

Financial PerformanceMoleculin Biotech announced 2Q25 financial results, posting EPS of ($0.49), compared to the estimate of ($0.41).

Market ExpectationsIf interim results are aligned with or slightly below the previous trial but still outperform cytarabine, this could positively impact the company's stock.

Moleculin Biotech News

Moleculin Biotech announces exercise of warrants for $6M gross proceeds

Moleculin Biotech (MBRX) entered into agreements with certain holders of its existing warrants for the immediate exercise of...

45m ago

MBRX

Moleculin Biotech announces OS data from Phase 1B/2 clinical trial in AML

Moleculin Biotech (MBRX) announced the completion of its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine...

1d ago

MBRX

Moleculin Biotech reports Q2 EPS (49c) vs. ($1.70) last year

“The second quarter of 2025 marked a period of momentum for Moleculin. We continued to make meaningful progress...

15d ago

MBRX

Moleculin Biotech sees cash runway into Q4

As of June 30, 2025, the Company had cash and cash equivalents of $7.6 million and believes that...

15d ago

MBRX

Moleculin Biotech announces preclinical data of annamycin in liver cancer

Moleculin Biotech (MBRX) announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known...

22d ago

MBRX

Moleculin Biotech receives notice of intent to grant new European patent

Moleculin Biotech (MBRX) announced it has received a Notice of Intent to Grant for the European patent application...

29d ago

MBRX

Optimistic Buy Rating for Moleculin Biotech Based on Promising Annamycin Data and Future Potential

Sara Nik, an analyst from H.C. Wainwright, reiterated the Buy rating on Moleculin Biotech. The associated price target...

22h ago

MBRX

Moleculin Biotech Completes Promising Annamycin Trial

The latest update is out from Moleculin Biotech ( ($MBRX) ). On August 27, 2025, Moleculin Biotech announced...

1d ago

MBRX

Moleculin Biotech Holds 2025 Annual Stockholders Meeting

The latest update is out from Moleculin Biotech ( ($MBRX) ). On August 18, 2024, Moleculin Biotech held...

10d ago

MBRX

Moleculin Biotech Releases New Corporate Presentation

Moleculin Biotech ( ($MBRX) ) has provided an update. On August 18, 2025, Moleculin Biotech, Inc. announced the...

10d ago

MBRX

Promising Outlook for Moleculin Biotech Amidst Phase 3 Trial Progress and Strong Financial Position

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech and keeping the price target...

14d ago

MBRX

Moleculin Biotech Reports Q2 2025 Financial Results

Moleculin Biotech ( ($MBRX) ) has released its Q2 earnings. Here is a breakdown of the information Moleculin...

14d ago

MBRX

Promising Developments in Annamycin Drive Buy Rating for Moleculin Biotech

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Moleculin Biotech, with...

15d ago

MBRX

Moleculin Biotech (MBRX) Q2 Earnings Cheat Sheet

Moleculin Biotech (MBRX) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street analysts...

17d ago

MBRX

MBRX FAQ

What was Moleculin Biotech’s price range in the past 12 months?

Moleculin Biotech lowest stock price was $0.25 and its highest was $3.65 in the past 12 months.

What is Moleculin Biotech’s market cap?

Moleculin Biotech’s market cap is $16.52M.

When is Moleculin Biotech’s upcoming earnings report date?

Moleculin Biotech’s upcoming earnings report date is Nov 17, 2025 which is in 81 days.

How were Moleculin Biotech’s earnings last quarter?

Moleculin Biotech released its earnings results on Aug 13, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.43 by -$0.06.

Is Moleculin Biotech overvalued?

According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Moleculin Biotech pay dividends?

Moleculin Biotech does not currently pay dividends.

What is Moleculin Biotech’s EPS estimate?

Moleculin Biotech’s EPS estimate is -0.27.

How many shares outstanding does Moleculin Biotech have?

Moleculin Biotech has 30,286,167 shares outstanding.

What happened to Moleculin Biotech’s price movement after its last earnings report?

Moleculin Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.43. Following the earnings report the stock price went up 1.515%.

Which hedge fund is a major shareholder of Moleculin Biotech?

Currently, no hedge funds are holding shares in MBRX

Company Description

Moleculin Biotech

Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates. The company operates primarily in the biotechnology sector, specializing in the research and development of novel anti-cancer agents. Moleculin's core products include a portfolio of small-molecule drug candidates targeting highly resistant tumors and hard-to-treat cancers. The company's lead compounds are designed to disrupt cancer cell metabolism and enhance the body's immune response against tumors.

Moleculin Biotech (MBRX) Earnings & Revenues

Historic Earnings Reports

MBRX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects significant progress in clinical trials and regulatory approvals, particularly for Annamycin. New patents and drug names bolster future market positioning. However, financial constraints and potential EU approval delays pose challenges.View all MBRX earnings summaries

MBRX Stock 12 Month Forecast

Average Price Target

$7.00

▲(1047.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","-1":"-$1","2.75":"$2.75","6.5":"$6.5","10.25":"$10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.75,6.5,10.25,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,1.6092307692307692,2.5584615384615383,3.5076923076923077,4.4569230769230765,5.406153846153846,6.355384615384615,7.304615384615385,8.253846153846153,9.203076923076923,10.152307692307692,11.101538461538462,12.05076923076923,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,1.1476923076923078,1.6353846153846154,2.123076923076923,2.6107692307692307,3.098461538461539,3.5861538461538465,4.073846153846154,4.561538461538461,5.049230769230769,5.5369230769230775,6.024615384615385,6.512307692307693,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,0.916923076923077,1.1738461538461538,1.4307692307692308,1.6876923076923078,1.9446153846153846,2.2015384615384614,2.4584615384615387,2.7153846153846155,2.9723076923076923,3.229230769230769,3.4861538461538464,3.743076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.06,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >